Stock CELU CELULARITY INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Celularity Inc.

Equities

CELU

US1511902041

Delayed Nasdaq
Other stock markets
 10:55:08 2024-06-28 EDT 		5-day change 1st Jan Change
2.809 USD +0.33% Intraday chart for Celularity Inc. -7.90% +13.54%
06-03 Celularity Presents Data of the Effect of Its T-Cell Platform on Multiple Hematological and Solid Tumors At the American Society of Clinical Oncology Annual Meeting CI
05-21 Transcript : Celularity Inc. - Analyst/Investor Day

Press Releases

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Celularity Presents Data of The Effect of Its T-Cell Platform on Multiple Hematological And Solid Tumors at the American Society of Clinical Oncology (ASCO) Annual Meeting
AQ
Harnessing natural killer cells to combat age-related diseases
AQ
Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing
AQ
Celularity Data Published in Journal for ImmunoTherapy of Cancer Reveals Benefits of Placental Circulating T Cells for CAR-T Therapy
AQ
Celularity Inc. to Host Investor and Analyst Research and Development Day
AQ
Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing
AQ
Celularity Inc. to Host Investor and Analyst Research & Development Day
AQ
Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing
AQ
Celularity Abstract “Emerging Technologies for the Management and Protection of Tendon Injuries: Decellularized Placental Biomaterials” Accepted at ORS Tendon Conference 2024
AQ
Celularity Announces Net Sales Trending Ahead of Expectations for First Quarter 2024, Implements Planned 2024 SG&A Reductions and Manufacturing Ramp for Advanced Biomaterial Products
AQ
Celularity Announces Net Sales Trending Ahead of Expectations for First Quarter 2024; Implements Planned 2024 SG&A Reductions and Manufacturing Ramp for Advanced Biomaterial Products
AQ
Celularity to Present Data Showing Senescent Cell Elimination by Off-the-Shelf Natural Killer Cells Derived from Human Placental Cells
AQ
Celularity Receives Healthcare Common Procedure Coding System (HCPCS) Q Code Approval from the U.S. Centers for Medicare & Medicaid Services for Biovance® 3L
AQ
Celularity Submits Request to U.S. FDA for Orphan Drug Designation for PDA-002 Asset Treating Facioscapulohumeral Muscular Dystrophy
AQ
Celularity CEO to Present on Cell Therapy’s Potential to Improve Longevity at 2024 ABUNDANCE Summit
AQ
Celularity CEO to Present Keynote Address at 2024 Society for Brain Mapping and Therapeutics Annual World Congress
AQ
Celularity to Present Data Showing Cancer Tumor Reduction by Off-the-Shelf Cell Therapy Derived from Human Placental Cells
AQ
Celularity Announces 1-for-10 Reverse Stock Split
AQ
Celularity’s Tri-layer Decellularized, Dehydrated Human Amniotic Membrane Product Investigated as a Carrier of Induced Pluripotent Stem Cell Derived-Limbal Stem Cells in the Treatment of Severe Ocular Surface Disease
AQ
Celularity Announces Net Sales Expectations for First Quarter 2024 and Full Year 2024, Reiterates Advanced Biomaterial Product Commercial and Development Pipeline
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CELU Stock
  4. News Celularity Inc.
  5. Press Releases